Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 7
Submit an article Journal homepage
177
Views
5
CrossRef citations to date
0
Altmetric
Drug Profile

Panitumumab in metastatic colorectal cancer

Christopher M Hocking Department of Medical Oncology, The Queen Elizabeth Hospital, TQEH, Woodville, Australia; Department of Medical Oncology, The Queen Elizabeth Hospital, TQEH, Woodville, Australia
,
Amanda R Townsend Department of Medical Oncology, The Queen Elizabeth Hospital, TQEH, Woodville, Australia; Department of Medical Oncology, The Queen Elizabeth Hospital, TQEH, Woodville, Australia
&
Timothy J Price Department of Medical Oncology, The Queen Elizabeth Hospital, TQEH, Woodville, Australia. [email protected]; School of Medicine, University of Adelaide, Australia; Department of Medical Oncology, The Queen Elizabeth Hospital, TQEH, Woodville, Australia. [email protected]; School of Medicine, University of Adelaide, Australia
Pages 781-793 | Published online: 10 Jan 2014

References

  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA. Cancer J. Clin. 61(2), 69–90 (2011).
  • Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil–leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 22(7), 1209–1214 (2004).
  • Kopetz S, Chang GJ, Overman MJ et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol. 27(22), 3677–3683 (2009).
  • Peeters M, Price T. Biologic therapies in the metastatic colorectal cancer treatment continuum – applying current evidence to clinical practice. Cancer Treat. Rev. 38(5), 397–406 (2012).
  • Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann. Surg. Oncol. 13(10), 1271–1280 (2006).
  • Tomlinson JS, Jarnagin WR, DeMatteo RP et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J. Clin. Oncol. 25(29), 4575–4580 (2007).
  • Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a Phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30(28), 3499–3506 (2012).
  • Grothey A, Van Cutsem E, Sobrero A et al.; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet 381(9863), 303–312 (2013).
  • Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408–1417 (2009).
  • Jonker DJ, O’Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357(20), 2040–2048 (2007).
  • El Zouhairi M, Charabaty A, Pishvaian MJ. Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Gastrointest. Cancer Res. 4(1), 15–21 (2011).
  • Yang BB, Lum P, Chen A et al. Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clin. Pharmacokinet. 49(11), 729–740 (2010).
  • Jean GW, Shah SR. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy 28(6), 742–754 (2008).
  • Toffoli G, De Mattia E, Cecchin E, Biason P, Masier S, Corona G. Pharmacology of epidermal growth factor inhibitors. Int. J. Biol. Markers 22(1 Suppl. 4), S24–S39 (2007).
  • Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59(6), 1236–1243 (1999).
  • Giannopoulou E, Antonacopoulou A, Matsouka P, Kalofonos HP. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 29(12), 5077–5082 (2009).
  • Keating GM. Panitumumab: a review of its use in metastatic colorectal cancer. Drugs 70(8), 1059–1078 (2010).
  • Schneider-Merck T, Lammerts van Bueren JJ, Berger S et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J. Immunol. 184(1), 512–520 (2010).
  • Doi T, Ohtsu A, Tahara M et al. Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors. Int. J. Clin. Oncol. 14(4), 307–314 (2009).
  • Stephenson JJ, Gregory C, Burris H et al. An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors. Clin. Colorectal Cancer 8(1), 29–37 (2009).
  • Okines AF, Ashley SE, Cunningham D et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, Phase II/III REAL-3 trial. J. Clin. Oncol. 28(25), 3945–3950 (2010).
  • Weiner LM, Belldegrun AS, Crawford J et al. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin. Cancer Res. 14(2), 502–508 (2008).
  • Hecht JR, Mitchell E, Neubauer MA et al. Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer. Clin. Cancer Res. 16(7), 2205–2213 (2010).
  • Muro K, Yoshino T, Doi T et al. A Phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Jpn. J. Clin. Oncol. 39(5), 321–326 (2009).
  • Maughan TS, Adams RA, Smith CG et al.; MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised Phase 3 MRC COIN trial. Lancet 377(9783), 2103–2114 (2011).
  • Peeters M, Douillard JY, Van Cutsem E et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J. Clin. Oncol. 31(6), 759–765 (2013).
  • Price TJ, Hardingham JE, Lee CK et al. Impact of KRAS and BRAF gene mutation status on outcomes from the Phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J. Clin. Oncol. 29(19), 2675–2682 (2011).
  • Van Cutsem E, Köhne CH, Láng I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29(15), 2011–2019 (2011).
  • Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626–1634 (2008).
  • Douillard JY, Siena S, Cassidy J et al. Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 28(31), 4697–4705 (2010).
  • Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757–1765 (2008).
  • Peeters M, Price TJ, Cervantes A et al. Randomized Phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 28(31), 4706–4713 (2010).
  • De Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304(16), 1812–1820 (2010).
  • Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J. Clin. Oncol. 30(29), 3570–3577 (2012).
  • De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11(8), 753–762 (2010).
  • Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26(35), 5705–5712 (2008).
  • Tol J, Dijkstra JR, Klomp M et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur. J. Cancer 46(11), 1997–2009 (2010).
  • Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 28(7), 1254–1261 (2010).
  • Tie J, Gibbs P, Lipton L et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int. J. Cancer 128(9), 2075–2084 (2011).
  • Hecht JR, Mitchell E, Chidiac T et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27(5), 672–680 (2009).
  • Berlin J, Posey J, Tchekmedyian S et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin. Colorectal Cancer 6(6), 427–432 (2007).
  • Köhne CH, Hofheinz R, Mineur L et al. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J. Cancer Res. Clin. Oncol. 138(1), 65–72 (2012).
  • Bokemeyer C, Bondarenko I, Hartmann JT et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann. Oncol. 22(7), 1535–1546 (2011).
  • Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360(6), 563–572 (2009).
  • Saltz LB, Lenz HJ, Kindler HL et al. Randomized Phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J. Clin. Oncol. 25(29), 4557–4561 (2007).
  • Cohn AL, Shumaker GC, Khandelwal P et al. An open-label, single-arm, Phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Clin. Colorectal Cancer 10(3), 171–177 (2011).
  • Lacouture ME, Mitchell EP, Piperdi B et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a Phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J. Clin. Oncol. 28(8), 1351–1357 (2010).
  • Mitchell EP, Piperdi B, Lacouture ME et al. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Clin. Colorectal Cancer 10(4), 333–339 (2011).
  • Van Cutsem E, Peeters M, Siena S et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25(13), 1658–1664 (2007).
  • Van Cutsem E, Siena S, Humblet Y et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann. Oncol. 19(1), 92–98 (2008).
  • Peeters M, Siena S, Van Cutsem E et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 115(7), 1544–1554 (2009).
  • Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337–345 (2004).
  • Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22(7), 1201–1208 (2004).
  • Stintzing S, Kapaun C, Laubender RP et al. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int. J. Cancer 132(1), 236–245 (2013).
  • Petrelli F, Borgonovo K, Barni S. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target. Oncol. 10.1007/s11523-013-0257-x (2013) (Epub ahead of print).
  • Hecht JR, Patnaik A, Berlin J et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110(5), 980–988 (2007).
  • Metges J, Raoul J, Achour N et al. PANERB study: panitumumab after cetuximab-based regimen failure. J. Clin. Oncol. 28(Suppl.), Abstract e14000 (2010).
  • Wadlow RC, Hezel AF, Abrams TA et al. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist 17(1), 14 (2012).
  • Montagut C, Dalmases A, Bellosillo B et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat. Med. 18(2), 221–223 (2012).
  • Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int. J. Colorectal Dis. 26(7), 823–833 (2011).
  • Lenz HJ. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology (Williston Park, NY) 20(5 Suppl. 2), 5–13 (2006).
  • Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat. Rev. Cancer 6(10), 803–812 (2006).
  • Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am. J. Pathol. 163(1), 303–312 (2003).
  • Jatoi A, Dakhil SR, Sloan JA et al.; North Central Cancer Treatment Group. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (supplementary N03CB). Support. Care Cancer 19(10), 1601–1607 (2011).
  • Jatoi A, Rowland K, Sloan JA et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 113(4), 847–853 (2008).
  • Scope A, Agero AL, Dusza SW et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J. Clin. Oncol. 25(34), 5390–5396 (2007).
  • Perez-Soler R, Zou Y, Li T, Ling YH. The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab. Clin. Cancer Res. 17(21), 6766–6777 (2011).
  • Fakih M, Vincent M. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr. Oncol. 17(Suppl. 1), S18–S30 (2010).
  • Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin. Drug Saf. 11 (Suppl. 1), S9–S19 (2012).
  • Fakih MG, Wilding G, Lombardo J. Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin. Colorectal Cancer 6(2), 152–156 (2006).
  • Vincenzi B, Galluzzo S, Santini D et al. Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Ann. Oncol. 22(5), 1141–1146 (2011).
  • Vincenzi B, Santini D, Galluzzo S et al. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin. Cancer Res. 14(13), 4219–4224 (2008).
  • Vickers MM, Karapetis CS, Tu D et al. Association of hypomagnesemia with inferior survival in a Phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Ann. Oncol. 24(4), 953–960 (2013).
  • Trotta F, Leufkens HG, Schellens JH, Laing R, Tafuri G. Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: when differences have an impact on clinical practice. J. Clin. Oncol. 29(16), 2266–2272 (2011).
  • Okines A, Puerto OD, Cunningham D et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised Phase III NO16966 trial. Br. J. Cancer 101(7), 1033–1038 (2009).
  • Knijn N, Mekenkamp LJ, Klomp M et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br. J. Cancer 104(6), 1020–1026 (2011).
  • Santini D, Loupakis F, Vincenzi B et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 13(12), 1270–1275 (2008).
  • Tveit KM, Guren T, Glimelius B et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J. Clin. Oncol. 30(15), 1755–1762 (2012).
  • Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 13(11), 1152–1160 (2012).
  • Peeters M, Cohn A, Köhne CH, Douillard JY. Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma. Clin. Colorectal Cancer 11(1), 14–23 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.